ARTV · Artiva Biotherapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on ARTV. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About ARTV · Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Live Quote
BUY (score +7) · 12-1 mom 396.3% · RSI 59.2 · above_both · -26.8% from high
Targets blend Wall Street consensus (5 analysts: low $23.00 / mean $35.80 / high $41.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Triggered anti-signal gates for >10% dilution (48% follow-on) and low liquidity. Additionally, lacks tradable options infrastructure and traditional valuation metrics, making a publishable structure impossible.
Triggered anti-signal gates for >10% dilution (48% follow-on) and low liquidity. Additionally, lacks tradable options infrastructure and traditional valuation metrics, making a publishable structure impossible.
Artiva is a pre-revenue clinical-stage biotech with AlloNK (NK cell therapy) showing 71% ACR50 response in refractory RA patients — a strong Phase 2a signal that prompted FDA alignment on a Phase 3 registrational trial. The May 2026 follow-on offering raised $300M at $11.52, diluting shares by ~48%, which likely explains the recent stock pullback from ~$13 to $8.55. RA Capital — a 10% owner and board member — was the lead investor in that offering, buying ~6.5M new shares (P code), demonstrating conviction at current levels. The five Form 4 filings triggering this investigation are uniformly sell-to-cover transactions from RSU vest dates — not discretionary open-market sales. Diego Miralles's receipt of RSUs and options as a $600K/yr inducement hire is the only true equity-incentive signal in the cluster.